剂量升级的鲁克索利提尼布用于耐火性血细胞性淋巴细胞分裂症
Yue Song1,2, Xiaoli Li3, Xuefeng He1,2
1National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Frontiers in immunology
|July 17, 2023
概括
在血细胞淋巴细胞细胞瘤 (HLH) 中增加剂量的鲁克索利提尼布显示出有前途,50%的患者实现了缓解. 升高的sCD25水平可以预测治疗反应,表明管理耐火性HLH的潜力.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血细胞淋巴细胞瘤 (HLH) 是一种严重的,细胞因子驱动的疾病,具有对标准疗法的高耐药率.
- 卢克索利提尼布是一种JAK1/2抑制剂,向关键的HLH细胞因子,但其在不响应病例中的使用需要进一步调查.
- 超过30%的HLH患者对前线治疗不耐药,需要替代治疗策略.
研究的目的:
- 评估剂量升级的鲁克索利提尼布在HLH患者中对标准剂量耐药性的疗效和安全性.
- 为了确定潜在的生物标志物,预测对升级的鲁克索利提尼布治疗的反应.
- 评估接受剂量升级式 ruxolitinib.com 的患者的临床结果和生存率.
主要方法:
- 在未能响应标准剂量后,对八名HLH患者进行了回顾性分析,这些患者接受了鲁克索利提尼布剂量升级的治疗.
- 评估治疗的疗效,安全性和与临床和实验室参数的相关性.
- 评估与剂量升级相关的生存率和不良事件.
主要成果:
- 50% (4/8) 的患者实现了改善的缓解,其中两个患者在剂量升级后实现了完全缓解 (CR).
- HLH和基线sCD25水平的病因与治疗反应相关 (p=0.029和p=0.021,分别).
- 一个sCD25切断10000 pg/ml预测治疗效果 (AUC=0.8125,p=0.035); 2个月的整体存活率为75%,可管理的不良事件.
结论:
- 剂量升级的鲁克索利提尼布是耐火性HLH的可行和安全选择.
- 升高的sCD25水平可以指导在ruxolitinib治疗的HLH患者的早期化疗考虑.
- 这项研究提供了初步证据,用于在具有挑战性的HLH病例中优化ruxolitinib剂量.
相关概念视频
01:11Renal Failure: Dose Adjustments
123
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
123
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.2K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.2K